A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Zuranolone.
- Who it may be relevant to
- Registry conditions: Depression, Postpartum. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective, Observational Survey Study Assessing Effectiveness of Zuranolone in Improving PPD Symptoms in the Real-world Setting
Overview
In this study, researchers will learn more about how zuranolone affects the symptoms of postpartum depression, also known as PPD. Zuranolone is a drug that healthcare professionals can prescribe for adults with PPD. After giving birth, adults with PPD can suffer from symptoms such as tiredness, sadness, and a loss of interest in their daily activities. This study is known as an observational study, which means it collects health information about study participants after a healthcare professional has already prescribed treatment. Participants for this study will be found in the United States using a database from CVS Specialty Pharmacy. This will include anyone who was prescribed zuranolone between June 2025 and May 2026 and who filled the prescription within 1 year after the end of their pregnancy. The main goal of this study is to learn more about how zuranolone affects the participants' PPD symptoms. This will be measured using a questionnaire completed by participants called the Edinburgh Postnatal Depression Scale, also known as the EPDS. A higher score on the EPDS may indicate more severe PPD symptoms. The main question researchers want to answer in this study is: \- Do PPD symptoms change after treatment with zuranolone based on EPDS scores measured at Day 15? Researchers will also learn more about: * Changes in participants' EPDS scores from before treatment to Day 45, which is 30 days after treatment ends. * How many participants breastfeed their babies while taking zuranolone * How many participants do not start new medicine after finishing their zuranolone treatment * How many participants take new medicines after finishing zuranolone * How many participants already tried other medicines for their depression symptoms before joining this study * How many participants take other medicines in general while taking zuranolone This study will be done as follows: People who fill their zuranolone prescription through CVS Specialty Pharmacy will be contacted by email or phone to ask them about their interest in participating in the study. Those who agree to take part will answer written questions about their symptoms using the EPDS tool. They will also answer other survey questions about their background, environment, and general health information. Participants must take their first dose of zuranolone within 7 days of joining the study. Participants will then be asked to answer questions using the EPDS tools, 15 days and 45 days after taking the first dose of zuranolone.
Detailed description
The primary objective of this study is to assess the effectiveness of zuranolone in reducing postpartum depression (PPD) symptoms via the Edinburgh Postnatal Depression Scale (EPDS) at Day 15. The secondary objectives are to assess the effectiveness of zuranolone in reducing PPD symptoms via the EPDS at Day 15 and Day 45 in a subgroup of participants with moderate PPD at baseline, in reducing PPD symptoms via the EPDS at Day 45, to assess breastfeeding status during treatment with zuranolone at Day 45 and to characterize treatment usage across the 45-day period via self-reported survey questions.
Interventions
- Drug Zuranolone
Administered as specified in the treatment arm
Primary outcome measures
- Change From Baseline in Edinburgh Postnatal Depression Scale (EPDS) at Day 15 [Time frame: Baseline (Day 0), Day 15]
Secondary outcome measures (11)
- Change From Baseline in EPDS at Day 45 [Time frame: Baseline (Day 0), Day 45]
- Change From Baseline in EPDS in Participants With Moderate Postpartum Depression (PPD) Severity at Days 15 and 45 [Time frame: Baseline (Day 0), Days 15 and 45]
- Number of Participants That Self-Report no New Initiation of Medication After Completion of Zuranolone [Time frame: Day 45]
- Number of Participants With Moderate PPD Severity That Self-Report no New Initiation of Medication After Completion of Zuranolone [Time frame: Day 45]
- Number of Participants That Self-Report Feeding Their Baby Breastmilk as Usual While Taking Zuranolone [Time frame: Day 45]
- Number of Participants That Self-Report History of Medication Use for Depression [Time frame: Day 0]
- Number of Participants With Moderate PPD Severity That Self-Report History of Medication Use for Depression [Time frame: Day 0]
- Number of Participants That Self-Report Prior Lines of Treatment for Their Current PPD Episode [Time frame: Day 0]
- Number of Participants With Moderate PPD Severity That Self-Report Prior Lines of Treatment for Their Current PPD Episode [Time frame: Day 0]
- Number of Participants That Self-Report Concomitant Medication Use With Zuranolone for the Treatment of PPD [Time frame: Day 0]
- Number of Participants With Moderate PPD Severity That Self-Report Concomitant Medication Use With Zuranolone for the Treatment of PPD [Time frame: Day 0]
Eligibility criteria
Inclusion criteria
- Adults who were prescribed and had one successful fill for zuranolone within 12 months following end of pregnancy for the treatment of PPD from June 2025 to May 2026 through CVS Specialty Pharmacy.
- Currently reside in the United States.
- Able to complete the questionnaires independently.
Exclusion criteria
- Prior fill of zuranolone or brexanolone in last 12 months.
- Participants with 2 or more doses of zuranolone at the time of screening.
- Current or history of bipolar disorder.
- Failure to complete baseline surveys prior to 2nd dose of zuranolone.
- Pregnancy that ended more than 12 months ago.
Other protocol-defined Inclusion/Exclusion criteria may apply.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- CVS Health — Woonsocket
Identifiers
NCT: NCT07047820 · US-ZRN-12349